US-based supply chain solution provider Lakeside Holding Limited (NASDAQ: LSH), which specializes in the Asian market, has announced a strategic partnership agreement between its recently acquired Hupan Pharmaceutical (Hubei) Co., Ltd. and Sinopharm Group Hubei Co., Ltd., a subsidiary of China’s Sinopharm Group Co., Ltd (HKG: 1099). The financial details of the deal remain undisclosed, but it encompasses essential medicine storage, transportation, and logistics services.
Reflecting Growth in China’s Healthcare Logistics Market
This partnership highlights the increasing demand for specialized logistics and supply chain solutions within China’s healthcare market. Hupan Pharmaceutical will support Sinopharm Hubei’s comprehensive pharmaceutical distribution needs, ensuring high standards in the storage and transportation of pharmaceutical products, including refrigerated and frozen medications, peptide hormones, and other essential medical supplies.
Hupan Pharma’s Expertise in Complex Clinical Supply Requirements
The collaboration also showcases Hupan Pharmaceutical’s expertise in meeting the complex clinical supply requirements in oncology, antibiotics, large-volume infusions, and aesthetic medicine. This expertise is crucial for ensuring the integrity and efficacy of these critical pharmaceutical products throughout their supply chain journey.
Enhancing Lakeside’s Business Presence in China
In addition to the expected annual revenue of USD 7 million from the acquisition of Hupan Pharmaceutical, Lakeside Holding Limited aims to increase its business presence in China through the collaboration between Hupan Pharmaceutical and Sinopharm Hubei. This partnership is expected to generate additional revenues and strengthen Lakeside’s position in the Chinese pharmaceutical logistics sector.-Fineline Info & Tech
Leave a Reply